Mkt Cap$2.28T+0.45%
24h Vol$38.58B
BTC Dom56.5%
ETH Dom9.9%
F&G27Fear
BTC$64,319.00+0.31% ETH$1,873.04+0.77% USDT$0.9991-0.01% BNB$568.90+0.79% USDC$0.9999-0.01% XRP$1.10+0.69% SOL$74.36+0.65% TRX$0.3312+0.27% FIGR_HELOC$1.03+2.49% HYPE$58.10+1.44% DOGE$0.072+3.97% USDS$0.99990.00% RAIN$0.0138-2.16% LEO$9.70+0.72% ZEC$483.27-1.09% XMR$363.76+0.08% BTC$64,319.00+0.31% ETH$1,873.04+0.77% USDT$0.9991-0.01% BNB$568.90+0.79% USDC$0.9999-0.01% XRP$1.10+0.69% SOL$74.36+0.65% TRX$0.3312+0.27% FIGR_HELOC$1.03+2.49% HYPE$58.10+1.44% DOGE$0.072+3.97% USDS$0.99990.00% RAIN$0.0138-2.16% LEO$9.70+0.72% ZEC$483.27-1.09% XMR$363.76+0.08%
News

VRTX

Total Stories
2
Section
VRTX
Vertex Pharmaceuticals (VRTX) Jumps Premarket on Positive Kidney Drug Trial
Market Analysis

Vertex (VRTX) Stock Climbs Premarket After Late-Stage Kidney Drug Success

Vertex Pharmaceuticals surged in premarket trading after its kidney disease drug povetacicept met the main goal in a late-stage trial.

Tim FriesMar 10, 20263 min read